SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1957And, 6 months agorumor was that SNY was not satisfied with REGN manufacturing eMiljenko Zuanic-10/28/2016
1956CRL, finance.yahoo.com So, again SNY/REGN were not truthful when reporting delaMiljenko Zuanic110/28/2016
1955Another bad news, potential delay in Sar BLA: secfilings.nasdaq.com This is badMiljenko Zuanic-10/28/2016
1954From Bayer 3Q, Eylea sale @M409e, down from 418 in 2Q. REGN 3Q results may be unMiljenko Zuanic-10/26/2016
1953Lucentis US 3Q sales increase ~7% (relative to 2Q) to 373CHF, which bode well foMiljenko Zuanic-10/20/2016
1952investor.regeneron.com October 17, 2016 Regeneron and Teva Provide Update on FBiotech Jim-10/17/2016
1951Just to make it clear, Regeneron rinucumab P1/2a data were very weak, and only Miljenko Zuanic-9/30/2016
1950Yes, he orchestrated Macugem high valuation. But, is there possibility that FlovMiljenko Zuanic-9/30/2016
1949LOL. David Guyer was the "brains" behind Eyetech's Macugen way bacDewDiligence_on_SI-9/30/2016
1948That CEO at OPHT is some guy. Real classy and really must believe int he PDGF mBiotech Jim-9/30/2016
1947Value of the manufacturing manager for bios (anyone remember old one?): biopharmMiljenko Zuanic-9/27/2016
1946Slide show for tomorrow just posted on the REGN web site. investor.regeneron.coBiotech Jim-9/21/2016
1945PFE is little bit ahead with P3 program, but nothing definitive. All are in gaMiljenko Zuanic-9/21/2016
1944So it's PFE/LLY and AMGN? Any idea on when the first Ph3 reads out for any Felix B19/21/2016
1943endpts.com According to John C., it is $2.6B deal + $500M (50% of the future devMiljenko Zuanic-9/20/2016
1942Whatever Regeneron do, it is viewed by Mr. Market as 'not enough"! finaMiljenko Zuanic-9/20/2016
1941investor.regeneron.com Nice gig if you can qualify. Some say advice is what yoBiotech Jim-9/14/2016
1940Nice review article on Fasinumab. news.morningstar.comMiljenko Zuanic-8/19/2016
1939Thoughts on today's earnings?Felix B-8/4/2016
1938Maybe fueled bit by desperation at Sanofi!Miljenko Zuanic-7/30/2016
1937yesMiljenko Zuanic-7/30/2016
1936Is this why it's running up recently?Felix B-7/29/2016
1935Bayer, Eylea 2Q 418e (~465$), +40% YoY....not bad ...Miljenko Zuanic-7/27/2016
1934Is REGN at the brink for another "inch higher" Eylea sales projection Miljenko Zuanic-7/21/2016
1933Indicator about HOT sector: fiercebiotech.com (anti-IL13)Miljenko Zuanic-7/8/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News